Jefferies Financial Group Reaffirms Buy Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by stock analysts at Jefferies Financial Group in a report released on Monday,Digital Look reports. They presently have a £150 price objective on the biopharmaceutical company’s stock. Jefferies Financial Group’s price objective would suggest a potential upside of 14.50% from the stock’s previous close.

Other analysts have also issued research reports about the stock. Shore Capital reaffirmed a “buy” rating and issued a £145 price objective on shares of AstraZeneca in a research report on Thursday. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research note on Monday, October 13th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a £110 price objective on shares of AstraZeneca in a research note on Wednesday, July 30th. Finally, Berenberg Bank raised their target price on AstraZeneca from £142 to £145 and gave the stock a “buy” rating in a research report on Tuesday, October 21st. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of £138.

AstraZeneca Trading Up 1.6%

LON AZN opened at £131 on Monday. The business’s fifty day moving average is £121.57 and its 200-day moving average is £112.42. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The stock has a market capitalization of £203.08 billion, a price-to-earnings ratio of 24.67, a PEG ratio of 0.86 and a beta of 0.17. AstraZeneca has a one year low of GBX 9,573.51 and a one year high of £131.06.

Insider Activity at AstraZeneca

In other news, insider Aradhana Sarin sold 9,563 shares of AstraZeneca stock in a transaction on Thursday, August 14th. The stock was sold at an average price of £115.12, for a total value of £1,100,892.56. 0.15% of the stock is owned by insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.